Liposomal and sublingual NAD products: what better absorption would need to prove

An absorption claim has more than one finish line

I would read “better absorbed” as the start of a question, rather than the end of a comparison. Better than which formulation, measured where, and linked to which outcome? A delivery system might change exposure without establishing a benefit in daily life. A product can also advertise a theory about delivery without supplying a human comparison of the finished formula.

Keep three possible claims separate. The first is that the ingredient reaches the circulation differently. The second is that a relevant tissue or biological measure changes. The third is that people experience a meaningful benefit. A persuasive explanation of the first does not eliminate the need to investigate the other two.

Match the ingredient before comparing the package

Human trials have studied oral NR and oral NMN as distinct ingredients. Martens studied NR in a six-week crossover design; Yoshino studied NMN for ten weeks in selected women with prediabetes. Neither is a head-to-head trial of the retail liposomal and sublingual products a shopper may see today. ^{[1] [2]}

A branded delivery term should therefore be added to the product identity, not used to replace it. Write down the ingredient first, then the route, formulation and other actives. Oral NAD+, oral NR and oral NMN cannot be merged into a single row just because a seller places all three in a cellular-health category.

Our ingredient guide explains the distinctions. For a shopping comparison, the Renue By Science review considers a liposomal NMN product, while the Tru Niagen review considers NR capsules. Their different labels are part of the comparison, not proof that one delivery method is superior.

An absorption claim, unpacked

A blood measurement needs a method and a clock

If an absorption graph is supplied, ask when the samples were taken and what was measured. A concentration at one time point is not the same thing as total exposure over time. A change in a downstream metabolite also needs interpretation; it should not automatically be labeled intact ingredient delivery.

Grant’s NAD+ infusion pilot illustrates the importance of timing. Its plasma and urine measurements were collected across a short, defined observation period during and after infusion. It did not compare that procedure with a sublingual product or determine which routine improves health more. ^[3]

This is why I would resist a chart that places percentages from separate studies on one common scale. Different sample types, timing and study populations can make the numbers incomparable. A large arrow in one experiment and a small arrow in another are not a randomized formulation comparison.

Faster is not automatically more useful

A claim about faster exposure still needs an outcome. If the promise concerns daily function, ask whether the speed difference changed that function. If the promise concerns a sustained response, ask whether the study measured persistence. A time-to-peak result might be scientifically interesting without settling either practical question.

Likewise, slower release is not automatically better. It may be part of a formulation rationale, but the rationale needs a relevant experiment. Without one, the reader is being asked to accept a design intention as evidence of an advantage. I would record that distinction directly in my comparison rather than award the formulation a benefit score.

FDA’s explanation of biomarkers and surrogate endpoints supplies the broader rule: predicting a clinical benefit requires validation in context. A measurement’s connection to an appealing mechanism does not, by itself, establish that prediction. ^[4]

What a useful formulation study would show

Look for a complete description of the tested products and a comparison that matches the advertisement. Were the active amounts comparable? Were other ingredients different? Were participants assigned in a way that helps reduce bias? A study of one payload cannot prove a universal absorption percentage for every substance placed in a liposome.

Next, separate analytical uncertainty from clinical uncertainty. The researchers may have a precise assay while the sample is small, or a clear exposure result while daily outcomes were never measured. Both limitations belong in the summary. “Human study” is not a single quality category that makes every remaining question disappear.

Finally, check whether the result was independently repeated. One exploratory experiment may justify further investigation, but a seller should describe it at that level. Ask for the original paper or complete study report, including methods and conflicts of interest, rather than relying only on a company’s headline graph. That request can be reasonable even when you like the product’s routine.

Quality testing answers another useful question

A batch certificate can support a statement about the tested product’s identity, quantity or contaminants, depending on the methods shown. It cannot establish an absorption benefit simply by existing. Check that the report corresponds to the actual lot and finished formulation, then keep its conclusion within the tests performed.

This distinction helps avoid an all-or-nothing judgment. A product may present useful testing records while its delivery advantage remains incompletely demonstrated. You can give credit for the records without treating them as a substitute for a human comparison. Conversely, a promising ingredient paper does not identify what is in an unverified bottle.

How I would compare the premium

Put the price difference beside the evidence difference. What additional claim are you paying for, and how directly has it been tested? A hypothetical premium of $20 per bottle might be acceptable for convenience or preference, but it should not be justified with an assumed benefit the study did not measure. That is a budgeting judgment, not a medical recommendation.

Use a common quantity and billing period in the cost worksheet. Also compare return conditions and whether the order renews automatically. Those practical terms are easy to overlook when the page is dominated by a molecular illustration.

My conclusion is not that every novel delivery system is useless. It is that a meaningful comparison needs the exact formula, an appropriate human comparison, a defined measurement and a clearly limited conclusion. Until those elements are supplied, I would describe the advantage as a claim to evaluate rather than a demonstrated reason to expect better health.

For capsule offers, the supplement label comparison keeps ingredient, serving and package cost together without ranking medical effects.